拜耳-话题@MedSci

#拜耳#

119篇内容 | 2994人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1318438, encodeId=2ba4131843845, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=后生可畏，拜耳眼科药物Eylea第4个适应症获欧盟批准, objectType=article, longId=47529, objectId=cb1f4e529ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1f4e529ab, replyNumber=0, likeNumber=92, createdTime=2015-03-02, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1f4e529ab, moduleTitle=后生可畏，拜耳眼科药物Eylea第4个适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb1f4e529ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318437, encodeId=a989131843e08, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳造影剂Gadavist新适应症获FDA批准，用于两周岁以下患儿, objectType=article, longId=45126, objectId=e0a5451262d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0a5451262d, replyNumber=0, likeNumber=68, createdTime=2015-01-09, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0a5451262d, moduleTitle=拜耳造影剂Gadavist新适应症获FDA批准，用于两周岁以下患儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0a5451262d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318435, encodeId=6e621318435e2, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=CHMP支持批准拜耳抗癌药Stivarga用于GIST的治疗, objectType=article, longId=37289, objectId=c6183e28946, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6183e28946, replyNumber=0, likeNumber=57, createdTime=2014-07-04, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6183e28946, moduleTitle=CHMP支持批准拜耳抗癌药Stivarga用于GIST的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6183e28946)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318436, encodeId=72e8131843602, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=CHMP建议批准拜耳眼科药物Eylea用于DME的治疗, objectType=article, longId=37290, objectId=a8003e2906f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8003e2906f, replyNumber=0, likeNumber=63, createdTime=2014-07-04, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8003e2906f, moduleTitle=CHMP建议批准拜耳眼科药物Eylea用于DME的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8003e2906f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318434, encodeId=ab421318434df, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=Dimension与拜耳签订2亿5千万美元合作协议, objectType=article, longId=37016, objectId=54db3e0162d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54db3e0162d, replyNumber=0, likeNumber=104, createdTime=2014-06-27, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54db3e0162d, moduleTitle=Dimension与拜耳签订2亿5千万美元合作协议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54db3e0162d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318433, encodeId=6f2a131843312, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳多吉美（Nexavar）甲状腺癌新适应症获日本批准, objectType=article, longId=36875, objectId=dbda368e5c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbda368e5c8, replyNumber=0, likeNumber=70, createdTime=2014-06-25, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbda368e5c8, moduleTitle=拜耳多吉美（Nexavar）甲状腺癌新适应症获日本批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbda368e5c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318432, encodeId=7f8a1318432fa, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=默沙东宣布以142亿美元将健康消费品业务出售给拜耳, objectType=article, longId=34493, objectId=833334493b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=833334493b0, replyNumber=0, likeNumber=65, createdTime=2014-05-10, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=833334493b0, moduleTitle=默沙东宣布以142亿美元将健康消费品业务出售给拜耳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=833334493b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318431, encodeId=30ef13184317d, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳肺动脉高压药物Adempas获欧盟批准, objectType=article, longId=32705, objectId=5a5332e05c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a5332e05c2, replyNumber=0, likeNumber=48, createdTime=2014-04-03, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a5332e05c2, moduleTitle=拜耳肺动脉高压药物Adempas获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a5332e05c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318430, encodeId=491f1318430b9, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=NICE拒绝推荐拜耳前列腺癌新药Xofigo, objectType=article, longId=32361, objectId=a1b83236188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1b83236188, replyNumber=0, likeNumber=66, createdTime=2014-03-27, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1b83236188, moduleTitle=NICE拒绝推荐拜耳前列腺癌新药Xofigo, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1b83236188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318429, encodeId=df64131842974, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳多吉美（Nexavar）肝癌III期未达主要终点, objectType=article, longId=31832, objectId=f1413183272, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1413183272, replyNumber=0, likeNumber=54, createdTime=2014-03-14, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1413183272, moduleTitle=拜耳多吉美（Nexavar）肝癌III期未达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1413183272)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318428, encodeId=eb1913184284c, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳在日本提交Eylea DME新适应症申请, objectType=article, longId=31468, objectId=9003314688f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9003314688f, replyNumber=0, likeNumber=54, createdTime=2014-03-06, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9003314688f, moduleTitle=拜耳在日本提交Eylea DME新适应症申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9003314688f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318427, encodeId=c53a131842e91, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳启动Stivarga III期COAST研究, objectType=article, longId=30970, objectId=3b75309e0de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b75309e0de, replyNumber=0, likeNumber=45, createdTime=2014-02-23, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b75309e0de, moduleTitle=拜耳启动Stivarga III期COAST研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b75309e0de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318426, encodeId=f1e31318426b9, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳眼科药物Eylea III期VISTA-DME取得积极数据, objectType=article, longId=30694, objectId=d78b3069424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d78b3069424, replyNumber=0, likeNumber=64, createdTime=2014-02-18, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d78b3069424, moduleTitle=拜耳眼科药物Eylea III期VISTA-DME取得积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d78b3069424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318425, encodeId=e24a1318425e5, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=CHMP建议批准拜耳肺动脉高压药riociguat, objectType=article, longId=30025, objectId=a95730025de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a95730025de, replyNumber=0, likeNumber=70, createdTime=2014-01-28, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a95730025de, moduleTitle=CHMP建议批准拜耳肺动脉高压药riociguat, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a95730025de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318424, encodeId=3a261318424be, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳拟以约29亿美元收购挪威制药公司Algeta, objectType=article, longId=29946, objectId=16e729946a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16e729946a1, replyNumber=0, likeNumber=63, createdTime=2014-01-26, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16e729946a1, moduleTitle=拜耳拟以约29亿美元收购挪威制药公司Algeta, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16e729946a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318423, encodeId=d0cd1318423bb, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳肺动脉高压药物Adempas获日本批准, objectType=article, longId=29653, objectId=9d9b29653a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d9b29653a6, replyNumber=0, likeNumber=55, createdTime=2014-01-22, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d9b29653a6, moduleTitle=拜耳肺动脉高压药物Adempas获日本批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d9b29653a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318422, encodeId=f96d1318422dc, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳与北大联合成立新药研发和转化研究中心, objectType=article, longId=29191, objectId=4eb62919177, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eb62919177, replyNumber=0, likeNumber=62, createdTime=2014-01-11, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eb62919177, moduleTitle=拜耳与北大联合成立新药研发和转化研究中心, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eb62919177)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318421, encodeId=4ea113184218a, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳多吉美（Nexavar）新适应症用于分化型甲状腺癌获FDA批准, objectType=article, longId=27071, objectId=93e42e071ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93e42e071ee, replyNumber=0, likeNumber=50, createdTime=2013-11-27, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93e42e071ee, moduleTitle=拜耳多吉美（Nexavar）新适应症用于分化型甲状腺癌获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93e42e071ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318420, encodeId=ac34131842051, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳抗癌药Xofigo获欧盟批准, objectType=article, longId=26817, objectId=90a82681e63, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90a82681e63, replyNumber=0, likeNumber=67, createdTime=2013-11-22, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90a82681e63, moduleTitle=拜耳抗癌药Xofigo获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90a82681e63)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318419, encodeId=57f1131841913, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳肺动脉高压药物Adempas获FDA批准, objectType=article, longId=25275, objectId=c360252e551, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c360252e551, replyNumber=0, likeNumber=65, createdTime=2013-10-13, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c360252e551, moduleTitle=拜耳肺动脉高压药物Adempas获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c360252e551)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

拜耳

2020-05-29

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

后生可畏，拜耳眼科药物Eylea第4个适应症获欧盟批准

2015-03-02

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳造影剂Gadavist新适应症获FDA批准，用于两周岁以下患儿

2015-01-09

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

CHMP支持批准拜耳抗癌药Stivarga用于GIST的治疗

2014-07-04

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

CHMP建议批准拜耳眼科药物Eylea用于DME的治疗

2014-07-04

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

Dimension与拜耳签订2亿5千万美元合作协议

2014-06-27

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳多吉美（Nexavar）甲状腺癌新适应症获日本批准

2014-06-25

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

默沙东宣布以142亿美元将健康消费品业务出售给拜耳

2014-05-10

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳肺动脉高压药物Adempas获欧盟批准

2014-04-03

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

NICE拒绝推荐拜耳前列腺癌新药Xofigo

2014-03-27

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳多吉美（Nexavar）肝癌III期未达主要终点

2014-03-14

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳在日本提交Eylea DME新适应症申请

2014-03-06

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳启动Stivarga III期COAST研究

2014-02-23

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳眼科药物Eylea III期VISTA-DME取得积极数据

2014-02-18

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

CHMP建议批准拜耳肺动脉高压药riociguat

2014-01-28

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳拟以约29亿美元收购挪威制药公司Algeta

2014-01-26

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳肺动脉高压药物Adempas获日本批准

2014-01-22

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳与北大联合成立新药研发和转化研究中心

2014-01-11

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳多吉美（Nexavar）新适应症用于分化型甲状腺癌获FDA批准

2013-11-27

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳抗癌药Xofigo获欧盟批准

2013-11-22

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳肺动脉高压药物Adempas获FDA批准

2013-10-13

科室
- - 订阅+
  - 更多科室
工具
服务